This week, cannabis coverage focused on legalization efforts, medical applications and safety concerns, with emphasis on therapeutic uses and regulatory developments.
Tuesday, March 17, 2026 — top 10 across News, Studies, Policy, and Memes
A Tennessee bill proposes legalizing marijuana and directing tax revenue toward road infrastructure repairs.
‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair … →A homemade medical cannabis recipe created by a mother is now being commercially sold at Georgia dispensaries.
Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries →This article examines the scientific validity of roadside THC testing devices used in impaired driving enforcement and discusses Saskatchewan Government Insurance’s zero-tolerance policy.
The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News →A study examines both beneficial and adverse effects of medical marijuana, with clinical relevance to pain management and safety considerations.
Study highlights positive, negatives of medical marijuana – WKRN News 2 →West Virginia’s House passed legislation to allocate medical marijuana tax revenue, marking a significant policy development for the state’s cannabis program.
West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some … →Pediatricians issue warnings about cannabis use disorder in children and address concerns regarding minors’ accessibility to cannabis products.
Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube →Recent analysis shows cannabis extracts effectively reduce myofascial pain, according to clinical research with high-quality evidence of meaningful patient outcomes.
Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots →InMed Pharmaceuticals is shifting its business strategy from commodity cannabinoid production to focus on developing therapeutic cannabis programs.
InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non … →I cannot provide an accurate summary as the article content is incomplete. Please provide the full text to generate a one-sentence summary.
TPS Cannabis News – StratCann →Summary The prescription CBD oil market is projected to reach US$190.9 billion by 2032, growing at 23.48% annually, with clinical evidence supporting its use for pain management.
Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR →Digest-Level Clinical Commentary
Clinical Reflection on Current Cannabis Medicine Trends These items collectively signal that cannabis medicine is undergoing a critical transition from largely unregulated consumer access toward structured therapeutic development and regulatory frameworks, which presents both opportunities and safety concerns for clinical practice. The concurrent focus on pediatric cannabis use disorder, roadside THC testing standardization, and pharmaceutical-grade cannabinoid development suggests that evidence-based clinicians will increasingly need to differentiate between recreational products of variable quality and legitimate therapeutic applications, particularly as CBD and cannabis extracts gain market prominence for conditions like myofascial pain. While revenue allocation models indicate growing governmental acceptance, the clinical burden falls on practitioners to maintain skepticism about efficacy claims, educate patients about dependency risks in vulnerable populations, and advocate for the high-quality evidence standards that currently lag behind commercial enthusiasm.
These items reflect the ongoing tension between expanding cannabis legalization and medical regulation, with multiple jurisdictions moving toward both recreational and medical frameworks while clinical evidence continues to accumulate on therapeutic applications and public health concerns. The trend toward pharmaceutical development and standardized dosing of cannabis-derived compounds suggests a gradual shift toward more rigorous clinical integration, though regulatory pathways remain fragmented across states. Pediatric and safety concerns, alongside financial incentives from tax allocation, highlight the need for clinicians to stay informed about cannabis use patterns and potential therapeutic benefits in their patient populations.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: